Treatment of Clinically Significative diabetic Macular Edema: influence of Bevacizumab, Triamcinolone and the combination of both plus macular grid thermal laser Photocoagulation of subthreshold

Not Applicable

Completed

• Conditions: Diabetic clinically significative diffuse macular edema; Eye Diseases; Macular edema

• Registration Number: ISRCTN10939948
• Lead Sponsor: Opthalmological Foundation of the Mediterranean (Fundacion Oftalmologica del Mediterraneo) (Spain)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-05-15
• Study Completion: 2008-01-01
• Last Update Posted: 4 October 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Diabetic CSME not treated previously
2. Best Corrected Visual Acuity (BCVA) less than 20/40
3. Patient able to complete follow-up
4. Controlled diabetes

Exclusion Criteria

1. Other associated ocular pathology
2. Ocular surgery three months before the inclusion
3. Participating in other interventional studies

Study & Design

• Study Type: Interventional
• Study Design: Not specified